NatWest Group’s Myriad Genetics MYGN Stock Holding History

NatWest Group’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-17,575	Closed	-$659K	–	267
2015 Q3	$659K	Buy	+17,575	New	+$624K	0.01%	240
2015 Q2	–	Sell	-17,575	Closed	-$622K	–	410
2015 Q1	$622K	Buy	17,575 +929	+6%	+$33.3K	0.01%	290
2014 Q4	$567	Sell	16,646 -11,420	-41%	-$405K	﹤0.01%	297
2014 Q3	$1.08K	Sell	28,066 -9,563	-25%	-$357K	0.01%	249
2014 Q2	$1.46M	Sell	37,629 -17,361	-32%	-$646K	0.06%	225
2014 Q1	$1.88M	Sell	54,990 -1,230	-2%	-$38.1K	0.08%	179
2013 Q4	$1.18M	Buy	56,220 +5,961	+12%	+$151K	0.03%	393
2013 Q3	$1.18M	Buy	50,259 +18,562	+59%	+$527K	0.03%	372
2013 Q2	$852K	Buy	+31,697	New	+$919K	0.01%	495

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

NatWest Group's MYGN Position: Q4 2015 in Review

NatWest Group sold out of Myriad Genetics (MYGN) in Q4 2015, closing a stake of 17,575 shares — an estimated $659K sold.

NatWest Group first reported a position in MYGN in Q2 2013 and held it in 9 quarters. The position peaked at $1.88M in Q1 2014. 232 funds tracked by Wall St. Rank hold MYGN as of Q4 2015.

NatWest Group reported no remaining Myriad Genetics position as of Q4 2015 after selling out during the quarter.
NatWest Group sold 17,575 Myriad Genetics shares in Q4 2015, an estimated $659K.
NatWest Group first reported a position in Myriad Genetics in Q2 2013 and held it in 9 quarters.
NatWest Group's Myriad Genetics position peaked at $1.88M in Q1 2014.
232 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2015.

Based on NatWest Group's 13F filing for Q4 2015, filed 16 Feb 2016.